Medical Writing. Agustín Rivero, general director of the SNS and Pharmacy Basic Services Portfolio, believes that the arrival of new biosimilars is good news for the SNS. He calculates that the savings that these drugs can generate in five years are between 300 and 400 million, affecting a set of products that represents an expense of 1.500 million euros.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
